Delving into the Latest Updates on OncoTab, Inc. with Synapse

Overview

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Endocrinology and Metabolic Disease

Radionuclide Drug Conjugates (RDC)

Monoclonal antibody

Synthetic peptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Radionuclide Drug Conjugates (RDC)	2
Monoclonal antibody	2
Diagnostic radiopharmaceuticals	1
Synthetic peptide	1
Nanobody	1

Top 5 Target	Count

MUC1(Mucin-1)	5
CD3 x MUC1	1

Rationale: Transformed MUC1 (tMUC1) is a cancer-associated antigen that is overexpressed in >90% of triple-negative breast cancers (TNBC), a highly metastatic and aggressive subtype of breast cancer. TAB004, a murine antibody targeting tMUC1, has shown efficacy for the targeted delivery of therapeutics to cancer cells. Our aim was to evaluate humanized TAB004 (hTAB004) as a potential theranostic for TNBC. Methods: The internalization of hTAB004 in tMUC1 expressing HCC70 cells was assessed via fluorescent microscopy. hTAB004 was DOTA-conjugated and radiolabeled with Indium-111 or Actinium-225 and tested for stability and tMUC1 binding (ELISA, flow cytometry). Lastly, in vivo biodistribution (SPECT-CT), dosimetry, and efficacy of hTAB004 were evaluated using a TNBC orthotopic mouse model. Results: hTAB004 was shown to bind and internalize into tMUC1-expressing cells. A production method of ²²⁵Ac-DOTA-hTAB004 (yield>97%, RCP>97% SA=5 kBq/µg) and ¹¹¹In-DOTA-hTAB004 (yield>70%, RCP>99%, SA=884 kBq/µg) was developed. The labeled molecules retained their affinity to tMUC1 and were stable in formulation and mouse serum. In NSG female mice bearing orthotopic HCC70 xenografts, the in vivo tumor concentration of ¹¹¹In-DOTA-hTAB004 was 65 ± 15 %ID/g (120 h post injection). A single ²²⁵Ac-DOTA-hTAB004 dose (18.5 kBq) caused a significant reduction in tumor volume (P<0.001, day 22) and increased survival compared to controls (P<0.007). The human dosimetry results were comparable to other clinically used agents. Conclusion: The results obtained with hTAB004 suggest that the ¹¹¹In/²²⁵Ac-DOTA-hTAB004 combination has significant potential as a theranostic strategy in TNBC and merits further development toward clinical translation.

20 May 2018·Journal of Clinical Oncology

Development of targeted radiotherapy for triple negative breast cancer.

Author: Puri, Rahul ; Wu, Shu-ta ; Ilovich, Ohad ; Gottumukkala, Vijay ; Mukherjee, Pinku ; Coelho, Richard ; Moore, Laura Jeffords ; Kelly, Vanessa

e13112Background: Breast cancer (BC) remains a leading cause of cancer-related deaths worldwide. Triple negative breast cancer (TNBC) is an aggressive phenotype that comprises only 15-20% of all ne...

21 May 2017·Genes & Cancer

A tumor specific antibody to aid breast cancer screening in women with dense breast tissue

Article

Author: Mukherjee, Pinku ; Moore, Laura J. ; Puri, Rahul ; Roy, Lopamudra Das ; Zhou, Ru ; Livasy, Chad ; El-Khoury, Joe M. ; Dillon, Lloye M.

Screening for breast cancer has predominantly been done using mammography. Unfortunately, mammograms miss 50% cancers in women with dense breast tissue. Multi-modal screenings offer the best chance of enhancing breast cancer screening effectiveness. We evaluated the use of TAB004, an antibody that recognizes the tumor form of the glycoprotein MUC1 (tMUC1), to aid early detection of breast cancer. Our experimental approach was to follow tMUC1 from the tissue into circulation. We found that 95% of human breast cancer tissues across all subtypes stained positive for TAB004. In breast cancer cell lines, we showed that the amount of tMUC1 released from tumor cells is proportional to the cell's tMUC1 expression level. Finally, we showed that TAB004 can be used to assess circulating tMUC1 levels, which when monitored in the context of cancer immunoediting, can aid earlier diagnosis of breast cancer regardless of breast tissue density. In a blinded pilot study with banked serial samples, tMUC1 levels increased significantly up to 2 years before diagnosis. Inclusion of tMUC1 monitoring as part of a multi-modal screening strategy may lead to earlier stage diagnosis of women whose cancers are missed by mammography.

100 Deals associated with OncoTab, Inc.

Login to view more data

100 Translational Medicine associated with OncoTab, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

4

Preclinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

111In-DOTA-hTAB004 ( MUC1 )	Neoplasms More	Preclinical
225Ac-DOTA-hTAB004 ( MUC1 )	MUC1 positive Solid Tumors More	Preclinical
hTABO04-CD3 Bispecific ( CD3 x MUC1 )	Triple Negative Breast Cancer More	Preclinical
TAB-004 (OncoTab) ( MUC1 )	Breast Cancer More	Preclinical
tMUC1 Targeting Nanobody (OncoTab) ( MUC1 )	MUC1 positive Solid Tumors More	Discovery